CLSA Events

Executive Series: The Campbell Alliance Dealmakers’ Intentions Survey

In collaboration with

Campbell Alliance

Following a highly successful Super Session at the BIO International Convention, Campbell Alliance will share the results of its fourth annual Dealmakers’ Intentions Survey, the only forward-looking measure of deal-making activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.

In 2012, in-licensers are pushing risk down the food chain to out-licensers. Supply and demand is skewed heavily toward in-licensers demanding de-risked, late-stage assets in the most established therapeutic areas.

However, the number of de-risked assets is relatively lacking, making the 2012 licensing environment a scary one. Discount rates have been rising, which is driving the in-licensers to chase late-stage assets. For those who can accept a long investment horizon in the face of these pressures, a relative surplus of early-stage oncology assets may exist, representing true buying opportunities. Buying opportunities in off-the-beaten-path asset classes may also exist, especially for those in development stages. In short, safety will be expensive in 2012.

This highly interactive discussion will address these issues and others.

A comprehensive white paper summarizing the results will be distributed onsite at the event.


Jeron Eaves
Senior Practice Executive, Campbell Alliance

Neel Patel
Practice Executive, Campbell Alliance

What: The Campbell Alliance
Dealmakers’ Intentions Survey
When: Tuesday, October 16, 2012
Breakfast and Networking: 7:30AM – 8:00AM
Discussion: 8:00AM – 9:00AM
Where: OncoMed Pharmaceuticals, Inc.
800 Chesapeake Dr.
Redwood City, CA 94063-4748
Parking: Complimentary On-Site
Attire: Business attire suggested
Attendance: RSVP by October 12th is required
No on-site registrations accepted

Open to C-Suite Executives of
Life Sciences Companies Only.

Cost: BayBio Members – FREE
Non-Members – $75.00